ImmunoGen Financial Statements (IMGN)
|
|
|
|
Report date
|
|
|
01.03.2019 |
11.03.2020 |
01.03.2021 |
28.02.2022 |
01.03.2023 |
|
02.11.2023 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
53.8 |
82.3 |
132.3 |
108.8 |
108.8 |
|
393.2 |
|
Operating Income, bln rub |
|
|
-160.5 |
-92.2 |
-135.5 |
-220.9 |
-220.9 |
|
43.5 |
|
EBITDA, bln rub |
? |
|
-153.5 |
-65.7 |
-19.7 |
-217.5 |
-217.5 |
|
56.7 |
|
Net profit, bln rub |
? |
|
-167.9 |
-122.1 |
-66.7 |
-222.9 |
-222.9 |
|
53.0 |
|
|
OCF, bln rub |
? |
|
-166.4 |
-88.4 |
-78.6 |
-229.8 |
-229.8 |
|
-130.7 |
|
CAPEX, bln rub |
? |
|
5.25 |
2.85 |
0.917 |
1.36 |
1.36 |
|
1.51 |
|
FCF, bln rub |
? |
|
-171.7 |
-91.2 |
-79.5 |
-231.2 |
-231.2 |
|
-132.2 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
210.6 |
153.0 |
153.2 |
329.5 |
329.5 |
|
343.5 |
|
Cost of production, bln rub |
|
|
173.9 |
114.5 |
114.6 |
0.176 |
0.176 |
|
6.13 |
|
R&D, bln rub |
|
|
173.9 |
114.5 |
114.6 |
213.4 |
213.4 |
|
195.3 |
|
Interest expenses, bln rub |
|
|
10.7 |
17.0 |
23.2 |
4.17 |
4.17 |
|
4.27 |
|
|
Assets, bln rub |
|
|
295.8 |
235.7 |
355.1 |
348.9 |
348.9 |
|
822.1 |
|
Net Assets, bln rub |
? |
|
11.9 |
-76.1 |
89.6 |
155.8 |
155.8 |
|
561.6 |
|
Debt, bln rub |
|
|
2.06 |
26.8 |
23.9 |
15.2 |
15.2 |
|
72.1 |
|
Cash, bln rub |
|
|
262.3 |
176.2 |
293.9 |
275.1 |
275.1 |
|
605.5 |
|
Net debt, bln rub |
|
|
-260.2 |
-149.4 |
-270.0 |
-259.9 |
-259.9 |
|
-533.4 |
|
|
Ordinary share price, rub |
|
|
4.80 |
5.11 |
6.45 |
7.42 |
4.96 |
|
5.83 |
|
Number of ordinary shares, mln |
|
|
139.9 |
148.3 |
176.2 |
253.6 |
253.3 |
|
273.3 |
|
|
Market cap, bln rub |
|
|
672 |
758 |
1 136 |
1 882 |
1 257 |
|
1 594 |
|
EV, bln rub |
? |
|
412 |
608 |
866 |
1 622 |
997 |
|
1 060 |
|
Book value, bln rub |
|
|
12 |
-76 |
90 |
156 |
156 |
|
562 |
|
|
EPS, rub |
? |
|
-1.20 |
-0.82 |
-0.38 |
-0.88 |
-0.88 |
|
0.19 |
|
FCF/share, rub |
|
|
-1.23 |
-0.62 |
-0.45 |
-0.91 |
-0.91 |
|
-0.48 |
|
BV/share, rub |
|
|
0.09 |
-0.51 |
0.51 |
0.61 |
0.62 |
|
2.05 |
|
|
EBITDA margin, % |
? |
|
-285.1% |
-79.9% |
-14.9% |
-200.0% |
-200.0% |
|
14.4% |
|
Net margin, % |
? |
|
-311.9% |
-148.4% |
-50.4% |
-204.9% |
-204.9% |
|
13.5% |
|
FCF yield, % |
? |
|
-25.6% |
-12.0% |
-7.00% |
-12.3% |
-18.4% |
|
-8.30% |
|
ROE, % |
? |
|
-1 406% |
160.4% |
-74.4% |
-143.1% |
-143.1% |
|
9.44% |
|
ROA, % |
? |
|
-56.8% |
-51.8% |
-18.8% |
-63.9% |
-63.9% |
|
6.45% |
|
|
P/E |
? |
|
-4.00 |
-6.21 |
-17.0 |
-8.44 |
-5.64 |
|
30.1 |
|
P/FCF |
|
|
-3.91 |
-8.31 |
-14.3 |
-8.14 |
-5.44 |
|
-12.1 |
|
P/S |
? |
|
12.5 |
9.21 |
8.59 |
17.3 |
11.6 |
|
4.05 |
|
P/BV |
? |
|
56.3 |
-9.96 |
12.7 |
12.1 |
8.06 |
|
2.84 |
|
EV/EBITDA |
? |
|
-2.68 |
-9.26 |
-44.0 |
-7.46 |
-4.58 |
|
18.7 |
|
Debt/EBITDA |
|
|
1.70 |
2.27 |
13.7 |
1.19 |
1.19 |
|
-9.41 |
|
|
R&D/CAPEX, % |
|
|
3 315% |
4 025% |
12 496% |
15 643% |
15 643% |
|
12 933% |
|
|
CAPEX/Revenue, % |
|
|
9.75% |
3.46% |
0.69% |
1.25% |
1.25% |
|
0.38% |
|
| ImmunoGen shareholders |
